AD bacteria hypothesis crashesAfter raising US $76 million in 2018 "...data from their Phase II/III trial, announced in October, proved divisive. Although patients overall in the study saw no benefit from the drug, a subgroup ..."
Where have we heard this before?
https://endpts.com/cortexyme-switches-direction-announces-cost-reduction-after-fda-slaps-hold-on-dark-horse-alzheimers-candidate/